Craft

Kamada Pharmaceuticals

Stock Price

$5.1

2024-06-07

Market Capitalization

$297.3 M

2024-06-07

Revenue

$142.5 M

FY, 2023

Kamada Pharmaceuticals Summary

Company Summary

Overview
Kamada Pharmaceuticals is a company that develops plasma-derived protein therapeutics for orphan indications. It uses its proprietary platform technology for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a liquid form as well as other plasma-derived Immune globulins. The company offers a line of pharmaceutical products intended for administration by injection or infusion.
Type
Public
Status
Active
Founded
1990
HQ
Rehovot, IL | view all locations
Website
https://www.kamada.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Amir London

    Amir London, CEO

    • Chaime Orlev
    • Michal Ayalon

      Michal Ayalon, VP, Research and Development

    • Eran Nir

    LocationsView all

    2 locations detected

    • Rehovot, Center District HQ

      Israel

    • Beit Kama, South District

      Israel

    Kamada Pharmaceuticals Financials

    Summary Financials

    Revenue (Q1, 2024)
    $37.7M
    Gross profit (Q1, 2024)
    $20.0M
    Net income (Q1, 2024)
    $2.4M
    Cash (Q1, 2024)
    $48.2M
    EBIT (Q1, 2024)
    $4.0M
    Enterprise value
    $249.1M

    Footer menu